Last reviewed · How we verify
NCT07217730: PHX-AFK-US
Healthcare Integrity & Anti-Fraud Enforcement
trial testing Validator-Governed Reform & Regulatory Escalation Protocol in Healthcare Fraud Schemes in 100 participants. Enrolling by invitation.
13 October 2034
Quick facts
| Lead sponsor | Truway Health, Inc. |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 13 October 2025 |
| Primary completion | 13 October 2034 |
| Estimated completion | 13 October 2034 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Validator-Governed Reform & Regulatory Escalation Protocol
- Coalition-Grade Validator Dashboard Module (CVDM-1)
- Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) — full drug profile →
Conditions studied
- Healthcare Fraud Schemes — all drugs for Healthcare Fraud Schemes →
- Kickback Networks — all drugs for Kickback Networks →
- Supply Chain Vulnerabilities — all drugs for Supply Chain Vulnerabilities →
- Governance Failures — all drugs for Governance Failures →
Sponsor
Truway Health, Inc. — full company profile →
Who can join
Eligibility, any sex, with Healthcare Fraud Schemes or Kickback Networks. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07217730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Truway Health, Inc. trials
Trials by the same sponsor.
- NCT07472023 — Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss · EARLY_PHASE1 · enrolling by invitation
- NCT07382804 — Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification · NA · enrolling by invitation
- NCT07321028 — Evaluation of In-Vitro Cryo Therapeutic Protocols on Human Cell Samples (TWH-CRYO-001) · EARLY_PHASE1 · enrolling by invitation
- NCT07221565 — Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine · Phase 1, PHASE2 · enrolling by invitation
- NCT07214896 — Deployment and Evaluation of Humanoid Robotics in Coalition-Aligned Clinical Care Settings · Phase 2 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07217730 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Truway Health, Inc.
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07217730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing